The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations
- Piscaglia, F.
- Bolondi, L.
- Aiani, L.
- Luigi Angeli
- M. , Arienti
- V. , Barozzi
- L. , Basilico
- R. , Bertolotto
- M. , Biasini
- E. , Busilacchi
- P. , Calliada
- F. , Caremani
- M. , Caturelli
- E. , Celli
- N. , Colecchia
- A. , Cova
- L.
- Assunta Cova
- M. , Crocetti
- L.
- de Sio
- I. , Drudi
- F. , Ferraioli
- C. , Fornari
- F. , Gaiani
- S. , Giangregorio
- F. , Giorgio
- A. , Ierace
- T. , Lencioni
- R. , Livraghi
- T. , Magnolfi
- F. , Martegani
- A. , Meloni
- F. , Menozzi
- G. , Pelosi
- G. , Pompili
- M. , Riccardi
- L. , Ricci
- P. , Rubaltelli
- L. , Sacerdoti
- D. , Serafini
- G. , Serra
- C. , Solbiati
- L. , Tacconi
- D. , Valentino
- M. , Vidili
- G. , Vitali
- F.
- CALLIADA, FABRIZIO
- FILICE, CARLO
DOIAbstract
Abstract: The aim of the present retrospective study was to assess the incidence of adverse events (AE) of a second-generation ultrasound contrast agent in real clinical practice. A total of 28 Italian Centres provided data on the postmarketing use of SonoVue (R) (Bracco Spa, Milan, Italy) in abdominal examination performed between December 2001 and December 2004. A total of 23 188 investigations were reported. No fatal event occurred. AEs were reported in 29 cases, of which only two were graded as serious; the rest, 27, were nonserious (23 mild, three moderate and one severe). The overall reporting rate of serious AE was 0.0086%. Overall, only four AEs required treatment (two serious, two nonserious including one moderate and one severe AE...
Add to ORKG